Your browser doesn't support javascript.
loading
Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5-6 years after completion of the primary series.
Park, Juliana; Archuleta, Sophia; Oh, May-Lin Helen; Shek, Lynette Pei-Chi; Jin, Jing; Bonaparte, Matthew; Fargo, Carina; Bouckenooghe, Alain.
Afiliación
  • Park J; Clinical Research and Development, Sanofi Pasteur, Singapore.
  • Archuleta S; Division of Infectious Diseases, University Medicine Cluster, National University Hospital, Singapore.
  • Oh MH; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Shek LP; Department of Medicine, Changi General Hospital, Singapore, Singapore.
  • Jin J; Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Bonaparte M; Biostatistics, Sanofi, Beijing, China.
  • Fargo C; Global Clinical Immunology department, Sanofi Pasteur, Swiftwater, PA, USA.
  • Bouckenooghe A; Clinical Research and Development, Sanofi Pasteur, Singapore.
Hum Vaccin Immunother ; 16(3): 523-529, 2020 03 03.
Article en En | MEDLINE | ID: mdl-31464558
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Dengue / Virus del Dengue / Vacunas contra el Dengue Tipo de estudio: Clinical_trials Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Hum Vaccin Immunother Año: 2020 Tipo del documento: Article País de afiliación: Singapur
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Dengue / Virus del Dengue / Vacunas contra el Dengue Tipo de estudio: Clinical_trials Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Hum Vaccin Immunother Año: 2020 Tipo del documento: Article País de afiliación: Singapur